Drug intelligence / Profile preview

SPO1101D

Development stage: Unknown
Lead developer: Seoul Pharma
Modality: Small Molecules, Drug Delivery Systems
Administration: Oral (orally Disintegrating Film)

Overview

SPO1101D is an orally disintegrating film (ODF) formulation of sildenafil developed by Seoul Pharma. It is designed to provide a convenient alternative to conventional sildenafil tablets, allowing for rapid dissolution in the mouth without the need for water. Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor primarily used for the treatment of erectile dysfunction and pulmonary arterial hypertension. The ODF formulation aims to improve patient compliance and onset of action compared to traditional formulations.

Brand names: Vultis
Other names: sildenafil citrate ODFsildenafil citrate orally-disintegrating film

Targets

PDE5 (Phosphodiesterase 5A)PDE6 (Phosphodiesterase 6)

Beyond the preview

Go deeper on SPO1101D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPO1101D.

Explore the full profile